Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Robert Kelley is active.

Publication


Featured researches published by Robert Kelley.


Circulation | 1992

Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure.

Robert J. Cody; Garrie J. Haas; Phillip Binkley; Quinn Capers; Robert Kelley

BackgroundEndothelin is a family of potent vasoconstrictor peptides of vascular endothelial origin. Although it has been proposed that the vasoconstrictor effects of endothelin are produced at the local vascular level, increased plasma concentration of endothelin has been identified in cardiovascular disorders. Methods and ResultsWe tested whether immunoreactive endothelin-1 could be detected by radioimmunoassay in plasma of congestive heart failure patients and whether levels correlated with hemodynamic characteristics. Twenty congestive heart failure patients (New York Heart Association class II-IV) were sampled in the morning after an overnight fast, before medication. Cardiac index was decreased to 2.14±0.45 l/m/m2, and pulmonary wedge pressure was increased to 22±7 mm Hg. The ranges of pulmonary pressures were: systolic, 22–100 mm Hg, mean, 13–61 mm Hg, and diastolic, 8–42 mm Hg. The endothelin-1 level was 9.07±4.13 pg/ml (range, 4–19 pg/ml), which was increased compared with 12 normals (3.7±0.6 pg/ml; range, 2.8–4.7 pg/ml); the difference was statistically significant (p<0.0001). Endothelin- 1 significantly correlated with pulmonary pressures (systolic, r=0.78; mean, r=0.80; diastolic, r=0.77; all p<0.003) and pulmonary vascular resistance (r=0.65, p<0.01). Endothelin- 1 strongly correlated with the resistance ratio (pulmonary vascular resistance/systemic vascular resistance) (r=0.88, p<0.0001). Stepwise multiple regression analysis confirmed the significance of these observations. ConclusionsElevated immunoreactive endothelin-1 specifically correlated with the extent of pulmonary hypertension in congestive heart failure patients. Whether endothelin-1 is a regional mediator of pulmonary hypertension or a marker for its occurrence requires additional evaluation.


American Journal of Pathology | 2001

Transgenic mice with cardiac-specific expression of activating transcription factor 3, a stress-inducible gene, have conduction abnormalities and contractile dysfunction.

Yoshichika Okamoto; Alysia A. Chaves; Jingchun Chen; Robert Kelley; Keith S. Jones; Harrison G. Weed; Kevin Gardner; Lisa Gangi; Mamoru Yamaguchi; Wuthichai Klomkleaw; Tomohiro Nakayama; Robert L. Hamlin; Cynthia A. Carnes; John Anthony Bauer; Tsonwin Hai

Activating transcription factor 3 (ATF3) is a member of the CREB/ATF family of transcription factors. Previously, we demonstrated that the expression of the ATF3 gene is induced by many stress signals. In this report, we demonstrate that expression of ATF3 is induced by cardiac ischemia coupled with reperfusion (ischemia-reperfusion) in both cultured cells and an animal model. Transgenic mice expressing ATF3 under the control of the alpha-myosin heavy chain promoter have atrial enlargement, and atrial and ventricular hypertrophy. Microscopic examination showed myocyte degeneration and fibrosis. Functionally, the transgenic heart has reduced contractility and aberrant conduction. Interestingly, expression of sorcin, a gene whose product inhibits the release of calcium from sarcoplasmic reticulum, is increased in these transgenic hearts. Taken together, our results indicate that expression of ATF3, a stress-inducible gene, in the heart leads to altered gene expression and impaired cardiac function.


Molecular and Cellular Biology | 1989

Involvement of tyrosyl-tRNA synthetase in splicing of group I introns in neurospora crassa mitochondria: Biochemical and immunochemical analyses of splicing activity

Arun Lahiri Majumder; Robert A. Akins; J. G. Wilkinson; Robert Kelley; A. J. Snook; Alan M. Lambowitz

We reported previously that mitochondrial tyrosyl-tRNA synthetase, which is encoded by the nuclear gene cyt-18 in Neurospora crassa, functions in splicing several group I introns in N. crassa mitochondria (R. A. Akins and A. M. Lambowitz, Cell 50:331-345, 1987). Two mutants in the cyt-18 gene (cyt-18-1 and cyt-18-2) are defective in both mitochondrial protein synthesis and splicing, and an activity that splices the mitochondrial large rRNA intron copurifies with a component of mitochondrial tyrosyl-tRNA synthetase. Here, we used antibodies against different trpE-cyt-18 fusion proteins to identify the cyt-18 gene product as a basic protein having an apparent molecular mass of 67 kilodaltons (kDa). Both the cyt-18-1 and cyt-18-2 mutants contain relatively high amounts of inactive cyt-18 protein detected immunochemically. Biochemical experiments show that the 67-kDa cyt-18 protein copurifies with splicing and synthetase activity through a number of different column chromatographic procedures. Some fractions having splicing activity contain only one or two prominent polypeptide bands, and the cyt-18 protein is among the few, if not only, major bands in common between the different fractions that have splicing activity. Phosphocellulose columns resolve three different forms or complexes of the cyt-18 protein that have splicing or synthetase activity or both. Gel filtration experiments show that splicing activity has a relatively small molecular mass (peak at 150 kDa with activity trailing to lower molecular masses) and could correspond simply to dimers or monomers, or both, of the cyt-18 protein. Finally, antibodies against different segments of the cyt-18 protein inhibit splicing of the large rRNA intron in vitro. Our results indicate that both splicing and tyrosyl-tRNA synthetase activity are associated with the same 67-kDa protein encoded by the cyt-18 gene. This protein is a key constituent of splicing activity; it functions directly in splicing, and few, if any, additional components are required for splicing the large rRNA intron.


American Journal of Cardiology | 1993

Effects of successful cardiac transplantation on plasma endothelin.

Garrie J. Haas; Margaret Wooding-Scott; Philip F. Binkley; P.David Myerowitz; Robert Kelley; Robert J. Cody

After cardiac transplantation, cyclosporine-treated patients exhibit a high incidence of systemic hypertension, the mechanism of which is not known. Endothelin, a potent vasoconstrictor peptide of endothelial origin, may be activated by cyclosporine-induced endothelial injury and therefore may mediate post-transplant hypertension. In the present study, we tested whether immunoreactive endothelin-1 could be detected by radioimmunoassay in the plasma of cardiac transplant recipients and if levels correlated with hemodynamic characteristics, cyclosporine level, or renal function as assessed by serum creatinine. Plasma endothelin was measured in 22 stable cyclosporine-treated patients 9 days to 3 years after successful orthotopic cardiac transplantation before routine hemodynamic assessment and surveillance endomyocardial biopsy. Fifteen patients were receiving chronic therapy for hypertension. Plasma endothelin-1 was 5.2 +/- 1.8 pg/ml (range 3.1 to 10.5), which was increased compared with that in 12 normal subjects (1.9 +/- 0.3 pg/ml; range 1.4 to 2.4); the difference was statistically significant (p < 0.0001). Repeated sampling in 8 patients at weekly intervals identified a persistent increase in endothelin with only modest variability. Endothelin-1 did not correlate with any hemodynamic variable, serum creatinine or cyclosporine level. Thus, endothelin-1 is increased after successful orthotopic cardiac transplantation. In the absence of discrete correlations with hemodynamic variables, serum creatinine or cyclosporine levels, both the characteristics and mechanisms for increased endothelin in recipients of cardiac transplants require further evaluation.


Annals of Emergency Medicine | 1993

Effect of standard-dose versus high-dose epinephrine on myocardial high-energy phosphates during ventricular fibrillation and closed-chest CPR

James W. Hoekstra; Robert Griffith; Robert Kelley; Robert J. Cody; Dave Lewis; Mark Scheatzle; Charles G. Brown

STUDY OBJECTIVE To evaluate the effects of standard-dose versus high-dose epinephrine on myocardial high-energy phosphate metabolism during resuscitation from cardiac arrest. DESIGN Prospective, nonrandomized, controlled study using a swine model of cardiac arrest and resuscitation. INTERVENTIONS After anesthesia, intravascular pressure instrumentation, and ten minutes of ventricular fibrillation arrest, closed-chest CPR was begun. After three minutes of CPR, animals were allocated to receive either 0.02 mg/kg i.v. standard-dose epinephrine (eight) or 0.2 mg/kg i.v. high-dose epinephrine (nine). The animals underwent thoracotomy and rapid-freezing transmural myocardial core biopsy for high-energy phosphate analysis 3.5 minutes after epinephrine administration. High-energy phosphate values were blindly determined using high-pressure liquid chromatography. RESULTS Intravascular pressure (mm Hg) and high-energy phosphate (nmol/mg protein) results for standard-dose epinephrine versus high-dose epinephrine are, respectively, coronary perfusion pressure, 15.3 +/- 7.8 versus 23.7 +/- 5.5 (P = .0009); phosphocreatine, 0.4 +/- 0.8 versus 6.2 +/- 4.4 (P = .0003); adenosine triphosphate, 9.8 +/- 4.8 versus 12.7 +/- 5.7 (P = .30); adenosine diphosphate, 5.4 +/- 2.1 versus 6.1 +/- 1.3 (P = .41); and adenylate charge, 0.68 +/- 0.12 versus 0.72 +/- 0.12 (P = .87). CONCLUSION High-dose epinephrine does not deplete myocardial high-energy phosphate when given in this model of prolonged ventricular fibrillation. High-dose epinephrine increases coronary perfusion pressure compared with standard-dose epinephrine. High-dose epinephrine administration repletes phosphocreatine during closed-chest CPR, thereby increasing myocardial energy stores.


Basic life sciences | 1986

Mitochondrial Plasmids of Neurospora and other Filamentous Fungi

Alan M. Lambowitz; Robert A. Akins; Robert Kelley; Suchira Pande; Frank E. Nargang

There is no generally agreed-to definition of a mitochondrial plasmid, and the different definitions used by various investigators have created some confusion in the literature. We propose that small DNA species present in mitochondria be classified as either defective mitochondrial DNAs (mtDNAs) or mitochondrial plasmids, depending on their origin. We define defective mtDNAs as those small DNA species that derived from the standard mtDNA by deletion and/or rearrangement of mtDNA sequences. Such mtDNAs are defective in the sense that they contain some, but not all, the information required for formation of functional mitochondria.


Cell | 1986

Mitochondrial Plasmids of Neurospora: Integration into Mitochondrial DNA and Evidence for Reverse Transcription in Mitochondria

Robert A. Akins; Robert Kelley; Alan M. Lambowitz


Molecular and Cellular Biology | 1989

Characterization of mutant mitochondrial plasmids of Neurospora spp. that have incorporated tRNAs by reverse transcription.

Robert A. Akins; Robert Kelley; Alan M. Lambowitz


American Journal of Physiology-heart and Circulatory Physiology | 2006

Endurance exercise training attenuates cardiac β2-adrenoceptor responsiveness and prevents ventricular fibrillation in animals susceptible to sudden death

George E. Billman; Monica Kukielka; Robert Kelley; Moustafa Moustafa-Bayoumi; Ruth A. Altschuld


Molecular and Cellular Biochemistry | 2008

Leptin modulates the negative inotropic effect of interleukin-1β in cardiac myocytes

M. Judith Radin; Bethany J. Holycross; Cristian Dumitrescu; Robert Kelley

Collaboration


Dive into the Robert Kelley's collaboration.

Top Co-Authors

Avatar

Alan M. Lambowitz

University of Texas at Austin

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge